

Cover Story
Free
By Matthew Bin Han Ong
The contract for operations and technical support at the Frederick National Laboratory for Cancer Research could be accepting proposals as early as next month—but NCI advisors said they are hoping to slow the recompetition process to reform the laboratory's mission.
In Brief


Drugs & Targets
Trending Stories
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation
- Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home













